Top Story
Halt to Pfizer, GSK trials tests e-clinical data savvy
Pfizer and GlaxoSmithKline have each entered the twilight zone of the drug business, via FDA's request that Pfizer halt a pain medication trial and its notification to GSK of a partial clinical hold for its large Avandia safety trial. Within that twilight zone lies the sector of subject data interruption, the navigation of which can help or hinder a drug throughout its lifecycle if, in fact, the drug survives the clinical hold. Read more
Latest News
Also Noted
> U.K. supplement makers and health food manufacturers are angry that regulators are beginning to demand clinical data that supports label claims. Blog | Video
> CRO Max Neeman International now offers CDISC services and modified solutions, including ongoing and legacy clinical data conversion, implementation of CDISC standards and CDISC compliance checks. Release
> Mobile drug reference tool maker Epocrates has named Jake Winebaum, an Internet incubator co-founder, to its board. Release
> Bay Clinic in Hawaii will receive $805,000 in stimulus funding over two years to support information technology improvements including hardware, a data center and enhancements to electronic practice management. Article
Read more >>Latest Comments
- And exactly what is Dr Nissen's relationship ...
- pinche doctor
- This looks like a sensible change that gets t...
- Although Alnylam has the potential to be the ...
- They did not cure Alzheimer, they only did de...
- You do realize that Rodman & Renshaw's resear...
- If they weren't discontinuing projects, then ...
Top News
Cancer trials halted amid investigations
Although modeling and simulation are likely to become fixtures in drug development, they do come with risks. Just ask Duke University. Enrollment has been suspended in three cancer treatment trials and investigators are now reviewing the data amassed from a project to test whether gene expression can help predict tumor response to drugs. Article
NCI plans clinical trial system reforms
Change is afoot at the National Cancer Institute, and clinical trials may never be the same again. NCI is becoming more data focused in drug development, according to new leadership, and is taking the clinical trial bull by the horns in wrangling onerous administrative and tech tasks in cooperative trials. Article
From The Network
Press Releases
- Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis
- Tethys Raises $33 Million
- Research Team Led by Pacific Biomarkers VP Amar Sethi Identifies Two Potential Diagnostic Markers for Ischemic Heart Disease
- Pacific Biomarkers Launches New Website
- Regeneron Reports Second Quarter 2010 Financial and Operating Results
- New biotech company grows from MCG diabetes and genomic research
